AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16886933 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 15248886 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-immediate implant placement (Im)
Number of subjects: 46
Study 15248886 — intervention group
Group type: COMPARATOR
Intervention: Delayed single-tooth implant placement (De)
Number of subjects: 46
Study 15248886 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implant treatment satisfaction (both groups)
Number of subjects: 46
Study 15248886 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic procedures
Number of subjects: 46
Study 15248886 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of implant surgery
Number of subjects: 46
Study 11740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine therapy (mean dose 136 +/‐ 22 microg/day)
Number of subjects: 12
Study 11740133 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study 9237937 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of ferrous gluconate (15 mg elemental iron) plus multivitamins
Number of subjects: 349
Study 9237937 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins
Number of subjects: 349
Study 8479488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (50 mg per day) plus pyrimethamine (50 mg per week)
Number of subjects: 349
Study 8479488 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg per month)
Number of subjects: 349
Study 2879489 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 9
Study 2879489 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 9
Study 2879489 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 9
Study 2879489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30789059 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐Adjust (n=10)
Number of subjects: 19
Study 30789059 — intervention group
Group type: COMPARATOR
Intervention: Befriending Therapy (n=9)
Number of subjects: 19
Study 30567595 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (1.0‐2.5 mg tid)
Number of subjects: 71
Study 27688786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 9
Study 27688786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 9
Study 27688786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN)
Number of subjects: 9
Study 25035080 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg) for 7 days
Number of subjects: 0
Study 25035080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22884662 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vaccinations with Vero cell-derived whole virus non-adjuvanted H5N1 vaccine (7.5 μg HA Antigen A/Vietnam/1203/2004)
Number of subjects: 561
Study 22884662 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccinations at 6, 12-15, and 24 months with 7.5 μg A/Indonesia/05/2005
Number of subjects: 561
Study 22884662 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccinations with 3.75 μg A/Indonesia/05/2005
Number of subjects: 561
Study 22884662 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose priming with 7.5 μg A/Vietnam/1203/2004 followed by a 12 month booster (7.5 μg)
Number of subjects: 561
Study 20418697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery and again 3 months later.
Number of subjects: 2991
Study 20418697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery.
Number of subjects: 2991
Study 20418697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered after surgery.
Number of subjects: 2991
Study 20418697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the SF-8 health-related quality-of-life questionnaire administered to women.
Number of subjects: 2991
Study 18405411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg kg‐1)
Number of subjects: 848
Study 18405411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.1 mg kg‐1)
Number of subjects: 848
Study 15747810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandible-protruding oral appliance
Number of subjects: 14
Study 12803833 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45
Study 12803833 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 45
Study 12803833 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 45
Study 10337858 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 8
Study 10337858 — intervention group
Group type: COMPARATOR
Intervention: Arginine
Number of subjects: 8
Study 7861016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg twice daily for patients > or = 60 kg
Number of subjects: 8127
Study 7861016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg twice daily for patients > or = 60 kg
Number of subjects: 8127
Study 7861016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 15 mg twice daily for patients weighing 40-59 kg
Number of subjects: 8127
Study 7861016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 30 mg twice daily for patients weighing 40-59 kg
Number of subjects: 8127
Study 7861016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 10 mg twice daily for patients weighing < 40 kg
Number of subjects: 8127
Study 7861016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg twice daily for patients weighing < 40 kg
Number of subjects: 8127
Study 2015169 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flosequinan
Number of subjects: 14
Study 2015169 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg flosequinan
Number of subjects: 14
Study 2015169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7129331 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 14
Study 7129331 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 14
Study 7129331 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine
Number of subjects: 14
Study 7129331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30762756 — intervention group
Group type: EXPERIMENTAL
Intervention: Active children with asthma
Number of subjects: 192
Study 30762756 — intervention group
Group type: COMPARATOR
Intervention: Active healthy children
Number of subjects: 192
Study 30762756 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive children with asthma
Number of subjects: 192
Study 30762756 — intervention group
Group type: COMPARATOR
Intervention: Inactive healthy children
Number of subjects: 192
Study 27917567 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% arginine bicarbonate
Number of subjects: 14
Study 27917567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% urea
Number of subjects: 14
Study 27917567 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF solution
Number of subjects: 14
Study 27917567 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 14
Study 25535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lobe resection via video-assisted thoracoscopy (VATS)
Number of subjects: 36
Study 25535772 — intervention group
Group type: COMPARATOR
Intervention: Unilateral sublobe resection via video-assisted thoracoscopy (VATS)
Number of subjects: 36
Study 24548981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 50 mg SC
Number of subjects: 20
Study 24548981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 100 mg SC
Number of subjects: 20
Study 24548981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg SC
Number of subjects: 20
Study 24548981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23073811 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-implant group
Number of subjects: 20
Study 23073811 — intervention group
Group type: COMPARATOR
Intervention: J-hook headgear group
Number of subjects: 20
Study 19526757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaiqin Chengqi Decoction (CQCQD) administered immediately after hospitalization (early-treated group)
Number of subjects: 40
Study 19526757 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medical therapy (same for both groups)
Number of subjects: 40
Study 19526757 — intervention group
Group type: COMPARATOR
Intervention: Chaiqin Chengqi Decoction (CQCQD) administered 3 days after hospitalization (late-treated group)
Number of subjects: 40
Study 17296341 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg once daily
Number of subjects: 1047
Study 17296341 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg once daily
Number of subjects: 1047
Study 17296341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1047
Study 15155394 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster-Stratton Parents and Children Series group parenting programme
Number of subjects: 116
Study 15155394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 11681436 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative culture of the subcutaneous catheter segment using roll-plate and sonication methods
Number of subjects: 479
Study 11681436 — intervention group
Group type: COMPARATOR
Intervention: Semiquantitative and quantitative catheter-tip cultures
Number of subjects: 479
Study 10216370 — intervention group
Group type: EXPERIMENTAL
Intervention: Antirejection therapy for Group I (10 patients) for 7 days
Number of subjects: 50
Study 10216370 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy for Group II (20 patients) for 2 weeks
Number of subjects: 50
Study 10216370 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic bacteriuria (Group II)
Number of subjects: 50
Study 10216370 — intervention group
Group type: COMPARATOR
Intervention: Acute pyelonephritis (Group II)
Number of subjects: 50
Study 10216370 — intervention group
Group type: COMPARATOR
Intervention: Patients with stable renal function (control group)
Number of subjects: 50
Study 7523479 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies to LH
Number of subjects: 300
Study 7523479 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified pituitary LH and immunoaffinity purified urinary LH
Number of subjects: 300
Study 7523479 — intervention group
Group type: COMPARATOR
Intervention: Commercially available LH assay kits
Number of subjects: 300
Study 3243014 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral grommet insertion
Number of subjects: 0
Study 3243014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter grommet (hypothetical consideration)
Number of subjects: 0
Study 31403944 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 70
Study 31403944 — intervention group
Group type: COMPARATOR
Intervention: Stretching and toning (SAT)
Number of subjects: 70
Study 28365225 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose regimen at 0 and 3 months (group 1)
Number of subjects: 1794
Study 28365225 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose at 0 months (group 2)
Number of subjects: 1794
Study 28365225 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose at 0 months and a booster at 12 months (group 3)
Number of subjects: 1794
Study 28365225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 1794
Study 25473078 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) for 8 weeks
Number of subjects: 26
Study 25473078 — intervention group
Group type: COMPARATOR
Intervention: Revaprazan for 8 weeks
Number of subjects: 26
Study 22543270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive relationship experiences
Number of subjects: 180
Study 22543270 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative couple interactions
Number of subjects: 180
Study 22543270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive couple interactions
Number of subjects: 180
Study 21175344 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 21175344 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 19696363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 14
Study 19696363 — intervention group
Group type: COMPARATOR
Intervention: Control (no HRT)
Number of subjects: 14
Study 18399039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and cognitive therapy (CT)
Number of subjects: 35
Study 18399039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and interpersonal therapy (IPT)
Number of subjects: 35
Study 15472659 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term nonsteroidal anti-inflammatory drugs and self-care instructions (palliative care group)
Number of subjects: 69
Study 15472659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs, self-care instructions, and occlusal appliance and mobilization therapy (physical medicine group)
Number of subjects: 69
Study 15472659 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 69
Study 15472659 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 69
Study 11868057 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 120
Study 11868057 — intervention group
Group type: COMPARATOR
Intervention: Conservative no-PTCA group
Number of subjects: 120
Study 9670410 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma interferon (gamma-IFN)
Number of subjects: 128
Study 9670410 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study 7924541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy
Number of subjects: 60
Study 7924541 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 60
Study 7924541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2507061 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25‐100 mg/day for 12 months, average dose 40 mg daily during the second six months)
Number of subjects: 32
Study 2507061 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 780037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Number of subjects: 26
Study 780037 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Number of subjects: 26
Study 780037 — intervention group
Group type: COMPARATOR
Intervention: Both oxprenolol and propranolol
Number of subjects: 26
Study 31278705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular NSAID Ketorolac injection
Number of subjects: 160
Study 31278705 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular Hyaluronic acid injection
Number of subjects: 160
Study 28489735 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational hypnosis session
Number of subjects: 97
Study 28489735 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 97
Study 24832381 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment group (n=11)
Number of subjects: 85
Study 24832381 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group (n=11)
Number of subjects: 85
Study 24832381 — intervention group
Group type: COMPARATOR
Intervention: Non-treated controls (n=13) after 6-12 months of follow-up
Number of subjects: 85
Study 24832381 — intervention group
Group type: COMPARATOR
Intervention: Uninfected patients (n=58)
Number of subjects: 85
Study 24050956 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (1.5 g p.o. BID)
Number of subjects: 742
Study 24050956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 21282040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic hydroxyapatite (HA)
Number of subjects: 10
Study 21282040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (HA)
Number of subjects: 10
Study 19815148 — intervention group
Group type: EXPERIMENTAL
Intervention: Light buccally directed orthodontic force of 25 g
Number of subjects: 10
Study 19815148 — intervention group
Group type: COMPARATOR
Intervention: Heavy orthodontic force of 225 g
Number of subjects: 10
Study 19815148 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary first premolars
Number of subjects: 10
Study 19815148 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal surface
Number of subjects: 10
Study 18693591 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 64
Study 18693591 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 64
Study 15328177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ep-CAM protein (400 microg/dose)
Number of subjects: 13
Study 15328177 — intervention group
Group type: COMPARATOR
Intervention: Anti-Id antibody (500 microg/dose)
Number of subjects: 13
Study 11210403 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone, 5 mg p.o. Q4H and levofloxacin, 500 mg p.o. 1 hour after starting oxycodone
Number of subjects: 8
Study 11210403 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin, 500 mg p.o. alone
Number of subjects: 8
Study 9468210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (25 mg/min IA)
Number of subjects: 15
Study 9468210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (oral therapy for 4 weeks)
Number of subjects: 15
Study 9468210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (acute treatment)
Number of subjects: 15
Study 9468210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (chronic treatment)
Number of subjects: 15
Study 9468210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8050539 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPP
Number of subjects: 155
Study 8050539 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 155
Study 2479252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg daily
Number of subjects: 20
Study 2479252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1960 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug beclomethasone dipropionate
Number of subjects: 20
Study 1960 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mug beclomethasone dipropionate
Number of subjects: 20
Study 1960 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mug beclomethasone dipropionate
Number of subjects: 20
Study 1960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28796130 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Peripheral (A-P) superset configuration
Number of subjects: 10
Study 28796130 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar Biomechanical (SB) superset configuration
Number of subjects: 10
Study 28796130 — intervention group
Group type: EXPERIMENTAL
Intervention: All superset protocols
Number of subjects: 10
Study 28796130 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonist-Antagonist (A-A) superset configuration
Number of subjects: 10
Study 31622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based, health literacy-sensitive diabetes management intervention
Number of subjects: 151
Study 31622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based, health literacy-sensitive diabetes management intervention
Number of subjects: 151
Study 31622033 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 151
Study 31622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based intervention
Number of subjects: 151
Study 31622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention
Number of subjects: 151
Study 28116151 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective MVPA (≥3 METs and ≥10 min)
Number of subjects: 595
Study 28116151 — intervention group
Group type: COMPARATOR
Intervention: Self-report MVPA
Number of subjects: 595
Study 28116151 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective SB (<1.5 METs)
Number of subjects: 595
Study 28116151 — intervention group
Group type: COMPARATOR
Intervention: Subjective SB
Number of subjects: 595
Study 26722513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (chemotherapy plus DC/CIK immunotherapy)
Number of subjects: 50
Study 23752288 — intervention group
Group type: EXPERIMENTAL
Intervention: P4HB sutures
Number of subjects: 22
Study 23752288 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 sutures
Number of subjects: 22
Study 23752288 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale and Hollander Wound Evaluation Scale
Number of subjects: 22
Study 21378634 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm skin disinfection (38°C)
Number of subjects: 10
Study 21378634 — intervention group
Group type: COMPARATOR
Intervention: Cold skin disinfection (20°C)
Number of subjects: 10
Study 19073787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone, 3 mg/m²/d for 16 weeks
Number of subjects: 11
Study 19073787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 11
Study 17042890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacological treatment
Number of subjects: 8
Study 17042890 — intervention group
Group type: COMPARATOR
Intervention: No psychosocial intervention (Control)
Number of subjects: 8
Study 15930482 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 19
Study 15930482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 19